Verrica Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Verrica Pharmaceuticals Inc. (VRCA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 76.09 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 39.84K shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 36.24K shares, a 85.65% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 19.46K shares, a 92.79% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was -147.02K shares, a 308.56% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month |
|---|---|---|---|
| 2026-06-30 | 39.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 76.09K shares 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 36.24K shares 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | 19.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -127.57K shares derived: sum of 2 quarters · filed 2025-11-14 | 124.93K shares 10-Q · filed 2025-11-14 |
| 2025-06-30 | -147.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 105.48K shares 10-Q · filed 2025-08-12 | |
| 2025-03-31 | 252.50K shares 10-Q · filed 2025-05-13 | ||
| 2024-09-30 | 269.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 340.40K shares derived: sum of 2 quarters · filed 2024-11-05 | 365.20K shares 10-Q · filed 2024-11-05 |
| 2024-06-30 | 70.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 95.29K shares 10-Q · filed 2024-08-14 | |
| 2024-03-31 | 24.80K shares 10-Q · filed 2024-05-13 | ||
| 2023-03-31 | 50.70K shares 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | 56.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 448.70K shares derived: sum of 2 quarters · filed 2022-11-07 | 462.94K shares 10-Q · filed 2022-11-07 |
| 2022-06-30 | 392.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 406.62K shares 10-Q · filed 2022-08-11 | |
| 2022-03-31 | 14.24K shares 10-Q · filed 2022-05-09 | ||
| 2021-09-30 | 359.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 359.35K shares derived: sum of 2 quarters · filed 2021-11-12 | 410.74K shares 10-Q · filed 2021-11-12 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 51.39K shares 10-Q · filed 2021-08-10 | |
| 2021-03-31 | 51.39K shares 10-Q · filed 2021-05-07 | ||
| 2020-09-30 | 121.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 121.31K shares derived: sum of 2 quarters · filed 2020-11-09 | 125.38K shares 10-Q · filed 2020-11-09 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | 4.07K shares 10-Q · filed 2020-08-05 | |
| 2020-03-31 | 4.07K shares 10-Q · filed 2020-05-07 | ||
| 2019-06-30 | 151.22K shares 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |